Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04299880
Title Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Boston Biomedical, Inc
Indications

Advanced Solid Tumor

Therapies

Gemcitabine + Nab-paclitaxel + Napabucasin

Napabucasin

Bevacizumab

Napabucasin + Paclitaxel

Napabucasin + Nivolumab

Fluorouracil + Irinotecan + Leucovorin + Napabucasin

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.